Bone Biologics Co. (NASDAQ:BBLGW – Get Free Report)’s stock price traded down 2.9% during trading on Wednesday . The stock traded as low as $20.20 and last traded at $20.20. 411 shares were traded during trading, a decline of 81% from the average session volume of 2,218 shares. The stock had previously closed at $20.80.
Bone Biologics Stock Down 2.9 %
The business’s 50-day moving average is $53.09 and its two-hundred day moving average is $46.02.
Bone Biologics Company Profile
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.
Read More
- Five stocks we like better than Bone Biologics
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- Stock Market Sectors: What Are They and How Many Are There?
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- How Investors Can Find the Best Cheap Dividend Stocks
- Why Energy Transfer Belongs on Your Watchlist
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
